Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus
Dario Didona(Istituto Dermopatico dell'Immacolata), Michael Hertl(Universitätsklinikum Gießen und Marburg), Júlia Richter Hummel(Information Today (United States)), Reinaldo Digigow(Information Today (United States)), Anna Zakrzewicz(Justus-Liebig-Universität Gießen), Sabine Fleischer(Universität Hamburg), Siegfried Rösch(Information Today (United States)), Julia Hinterseher(Philipps University of Marburg), Franziska Schauer(University of Freiburg), Christoph Hudemann(Philipps University of Marburg), Karolin Volkmann(Philipps University of Marburg), Simon Feldhoff(Justus-Liebig-Universität Gießen), Rüdiger Eming(Philipps University of Marburg), Matthias Hahn(University of Tübingen), Michael Sticherling(Universitätsklinikum Erlangen), Emiliano Antiga(University of Florence), Maik Hahmann(Philipps University of Marburg), Alexandra Polakova(Philipps University of Marburg), Roberto Maglie(Philipps University of Marburg), Daria Krzikalla(Information Today (United States)), Claudia Günther(University Children's Hospital Tübingen), Nina Magnolo(University Hospital Münster), Sandra Huguenin(Information Today (United States)), Farzan Solimani(Humboldt-Universität zu Berlin), Veronica Asnaghi(Information Today (United States)), Kamran Ghoreschi(National Institutes of Health), Holger Garn(Philipps University of Marburg), Ritva Tikkanen(Justus-Liebig-Universität Gießen), Erno van Schaick(Information Today (United States)), Stefano Senatore(University of Florence), Christian Möbs(Philipps University of Marburg), Christine L. Zimmer(Philipps University of Marburg), Kerstin Steinbrink(University of Münster), Rupert Sandbrink(Io Therapeutics (United States)), Susanne Harnisch(Philipps University of Marburg), Jörg Täubel(British Heart Foundation), Wolfgang Pfützner(Philipps University of Marburg), Antônio Carlos dos Santos(Universidade de São Paulo), Johannes Pohlner(Information Today (United States)), Shu-Hung Wang(Information Today (United States)), Frank S. Zollmann(Information Today (United States)), Cristina de Min(Therapeutics Clinical Research), Lukas Sollfrank(Universitätsklinikum Erlangen)
Cited by 5
Related Papers
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
|Neurology|2006|677
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
|The Journal of Immunology|2011|634
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
|American Journal of Ophthalmology|2006|551
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
|JAMA Neurology|2014|514